 trial prophylact ganciclovir cytomegaloviru pulmonari infect recipi allogen bone marrow transplant citi hope-stanford-syntex cmv studi group background cytomegaloviru cmv interstiti pneumonia major caus death allogen bone marrow transplant control trial ganciclovir recipi bone marrow transplant asymptomat pulmonari cmv infect risk factor develop cmv interstiti pneumonia method bone marrow transplant patient evid respiratori diseas underw routin bronchoalveolar lavag day patient posit cultur cmv prophylact ganciclovir observ ganciclovir mg kilogram bodi week time week day result culture-posit patient prophylact ganciclovir percent cmv pneumonia day culture-posit control patient percent rel risk patient full cours ganciclovir prophylaxi cmv interstiti pneumonia patient ganciclovir maxim serum creatinin level equal mumol liter mg decilit none control cmv-neg patient percent cmv pneumonia rate untreat cmv-posit control patient rel risk predictor cmv pneumonia lavage-fluid cultur posit cmv cmv-posit blood cultur specimen day conclus recipi allogen bone marrow asymptomat cmv infect lung major risk factor subsequ cmv interstiti pneumonia prophylact ganciclovir effect develop cmv interstiti pneumonia patient asymptomat infect